Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
6cm and approximately 1/3 have metastasized at the time of diagnosis. It often co-occurs with Zollinger-Ellison syndrome or multiple endocrine neoplasia type 1 (MEN 1).
Features include very common findings: Elevated circulating growth hormone concentration; and common findings: Coarse facial features, Abnormal abdomen morphology, Weight loss, and Diarrhea and others. 38 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 15 | Diarrhea, Nausea and vomiting, Constipation |
Biomarker and diagnostic research for GRFoma has been reported in the published literature.
Phenotype severity distribution: 1 very common feature, 16 common features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for GRFoma.
106 publications have been identified in PubMed for GRFoma. Research spans Basic Science / Preclinical (29%), Review / Meta-Analysis (20%), and Gene Therapy / Novel Therapeutics (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 31 | 29% |
Data assembled from 4 of 12 sources · Last updated Sep 17, 2026, 7:34 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about GRFoma
Hormones
4 |
Elevated circulating growth hormone concentration, Increased circulating cortisol level, Abnormality of the thyroid gland |
Growth and development | 2 | Elevated circulating growth hormone concentration, Weight loss |
Lab test results | 2 | Elevated circulating growth hormone concentration, Increased circulating prolactin concentration |
Skin | 2 | Palmoplantar hyperhidrosis, Subcutaneous lipoma |
Head and neck | 1 | Coarse facial features |
Lungs and breathing | 1 | Neoplasm of the lung |
21 |
20% |
New treatment approaches | 19 | 18% |
Testing and diagnosis research | 13 | 12% |
Clinical study results | 12 | 11% |
Patient case studies | 7 | 7% |
Disease patterns and progression | 3 | 3% |
Yao DQ (2026). [PMID: 40081403](https://pubmed.ncbi.nlm.nih.gov/40081403/). *RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin*. [Basic Science / Preclinical]
Erfani H (2026). [PMID: 42070324](https://pubmed.ncbi.nlm.nih.gov/42070324/). *Int J Gynecol Cancer*. [Review / Meta-Analysis]
Sudhakar D (2026). [PMID: 42051285](https://pubmed.ncbi.nlm.nih.gov/42051285/). *JCEM Case Rep*. [Case Report / Case Series]
Ni Y (2026). [PMID: 41968695](https://pubmed.ncbi.nlm.nih.gov/41968695/). *Med Phys*. [Diagnostic / Biomarker]
Wu H (2026). [PMID: 41730776](https://pubmed.ncbi.nlm.nih.gov/41730776/). *International journal of cancer*. [Epidemiology / Natural History]
Xiong T (2026). [PMID: 41474032](https://pubmed.ncbi.nlm.nih.gov/41474032/). *Medical physics*. [Clinical Trial Publication]
Cheng CH (2026). [PMID: 41845367](https://pubmed.ncbi.nlm.nih.gov/41845367/). *Mol Cancer*. [Basic Science / Preclinical]
Lamback E (2026). [PMID: 42007244](https://pubmed.ncbi.nlm.nih.gov/42007244/). *JCEM Case Rep*. [Case Report / Case Series]
Chen Z (2026). [PMID: 41832521](https://pubmed.ncbi.nlm.nih.gov/41832521/). *Radiat Oncol*. [Diagnostic / Biomarker]
Ezeala CC (2026). [PMID: 41893190](https://pubmed.ncbi.nlm.nih.gov/41893190/). *J Funct Biomater*. [Diagnostic / Biomarker]